LSL PHARMA GROUP SECURES $17.5 MILLION FROM DESJARDINS AND BDC
BOUCHERVILLE, QC, June 27, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (" LSL Pharma" or the " Corporation"), a Canadian integrated pharmaceutical company, today announced having secured a new $7.5 million operating line of credit (the "New Line of Credit") from Caisse Populaire Desjardins des Patriotes ("Desjardins") as well as new $10 million pari-passu term loan from BDC and Caisse Populaire Desjardins (the "Term Loan").
The New Line of Credit which is now available, represents a $4.2 million increase over the prior combined line of credit from TD Bank and Scotia Bank. The Term Loan financing expected to close on or about July 7, 2025 will be disbursed in three separate tranches. The first tranche to be disbursed on closing and serve to reimburse existing loans totalling $3.2 million plus accrued interest, as well as all outstanding Convertible Debentures listed asTSXV: LSL.DB, representing a principal amount of $3.288 million plus accrued interest (the "Redemption"). The Redemption will be subject to TSXV approval and a formal announcement and notice to Debenture holders, as per the terms of the Debenture Indenture dated November 1, 2023, which is available under LSL Pharma's issuer profile on www.sedarplus.ca.
The second and third tranches will be used to fund capital expenditures and serve to reimburse other debts and loans. Disbursement of the second and third tranches is subject to certain conditions and is expected to be made available before the end of the current fiscal year. The New loan once fully disbursed, will help reduce the Corporation's annual debt servicing requirements and contribute to lower the Corporation's overall interest costs.
Interest rate on the New Line of Credit as well as the Desjardins portion of the Term Loan will be based on Desjardins' prime rate plus 1%, which may be reduced based on financial criteria. The BDC portion of the Term Loan will be BDC's base rate plus 2.0% (the "Rate"). The Rate may be reduced by up to 2.5% should LSL Pharma meet certain financial criteria. The various portions of the New Loan will be amortized over 8 to 20 years, include a capital repayment moratorium for the first year on the BDC portion and will be subject to nominal financial covenants.
"We are pleased to announce this New Financing and thank Desjardins and BDC for supporting LSL Pharma and sharing our vision, as we keep implementing organic and strategic growth initiatives" said Francois Roberge, President and Chief Executive Officer. "The New Line of Credit and Term loan will significantly increase our working capital flexibility by providing us with in excess of $6 million of additional financing not allocated to loans/debt repayments", said Luc Mainville, Executive Vice-President and Chief Financial Officer.
Caution regarding forward-looking statements
This press release may contain forward-looking statements as defined under applicable Canadian securities legislation. Forward-looking statements can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "continue" or similar expressions. Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Corporation's ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, those identified in the Corporation's filings with Canadian securities regulatory authorities, such as legislative or regulatory developments, increased competition, technological change and general economic conditions. All forward-looking statements made herein should be read in conjunction with such documents.
Readers are cautioned not to place undue reliance on forward-looking statements. No assurance can be given that any of the events referred to in the forward-looking statements will transpire, and if any of them do, the actual results, performance or achievements of the Corporation may differ materially from those expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. The Corporation does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) have reviewed or accept responsibility for the adequacy or accuracy of this release.
About LSL Pharma Group Inc.
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Companies forming part of LSL Pharma Group are Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Santé Inc. and Dermolab Pharma Ltd. For further information, please visit our website at www.groupelslpharma.com.
SOURCE Groupe LSL PHARMA INC.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
KOOTENAY SILVER ANNOUNCES CLOSING OF $20 MILLION BOUGHT DEAL PUBLIC OFFERING, INCLUDING FULL EXERCISE OF THE OVER-ALLOTMENT OPTION
VANCOUVER, BC, June 27, 2025 /CNW/ - Kootenay Silver Inc. (" Kootenay" or the " Company") (TSXV: KTN) (OTCQX: KOOYF) is pleased to announce that the Company has completed its previously announced and upsized bought deal public offering 19,057,800 units of the Company (the " Units"), including the full exercise of the over-allotment option, at a price of $1.05 per Unit for gross proceeds to the Company of $20,010,690 (the " Offering"). The Offering was led by Research Capital Corporation as the lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters, including Red Cloud Securities Inc. (collectively, the " Underwriters"). Each Unit consists of one common share of the Company (each, a " Common Share") and one-half of one Common Share purchase warrant (each whole warrant, a " Warrant"). Each Warrant shall entitle the holder to purchase one Common Share of the Company at a price of $1.58 at any time on or before June 27, 2028. The net proceeds raised under the Offering will be used for the advancement of the Company's Columba Silver Project in Mexico as well as for general working capital and corporate purposes. The Offering was completed pursuant to a prospectus supplement of the Company filed in all of the provinces of Canada and dated June 19, 2025 that supplemented the short form base shelf prospectus of the Company dated March 27, 2024. The Offering remains subject to the final approval of the TSX Venture Exchange (the " TSXV"). In connection with the Offering, the Company paid the Underwriters a cash commission of $1,108,271.43 and issued to the Underwriters 1,055,497 broker warrants (the " Broker Warrants"). In addition, the Agents received an advisory fee of $62,000 plus tax and 59,400 advisory broker warrants on the same terms as the Broker Warrants. Each Broker Warrant entitles the holder thereof to acquire one Common Share at a price of $1.05 per Common Share at any time on or before June 27, 2028. The Company also paid aggregate cash finder's fees of $29,999.97 to certain arm's length finders in connection with Units purchased by certain president's list purchasers. The securities offered pursuant to the Offering have not been, nor will they be, registered under the U.S. Securities Act or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. About Kootenay Silver Inc. Kootenay Silver Inc. is an exploration company actively engaged in the discovery and development of mineral projects in the Sierra Madre Region of Mexico. Supported by one of the largest junior portfolios of silver assets in Mexico, Kootenay continues to provide its shareholders with significant leverage to silver prices. The Company remains focused on the expansion of its current silver resources, new discoveries and the near-term economic development of its priority silver projects located in prolific mining districts in Sonora, State and Chihuahua, State, Mexico, respectively. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. "Forward-looking information" includes, but is not limited to, statements with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future. Generally, but not always, forward-looking information and statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative connation thereof. Such forward-looking information and statements are based on numerous assumptions, including among others, that the Company will allocate the net proceeds of the Offering to exploration programs on a successful basis. Although the assumptions made by the Company in providing forward-looking information or making forward-looking statements are considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's plans or expectations include risks relating to receipt of TSXV approval for the Offering, risks relating to the ability of the Company to apply the use of proceeds from the Offering as anticipated and those risks set out in the Company's public documents filed on Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information or implied by forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Cision Canada
an hour ago
- Cision Canada
Mercanto Reports Q3 2025 Financial Results and Provides Operational Update
MONTREAL, June 27, 2025 /CNW/ - Mercanto Holdings Inc. (TSXV: MUSH) ("Mercanto" or the "Company"), released its financial results for the third quarter ended April 30, 2025. The Company also provided an operational update and reiterated its strategy amid an evolving cannabis market in Quebec and across Canada. Financial Highlights for Q3 2025 (vs. Q3 2024): The Company notes that while topline revenue declined compared to the same period last year, results reflect the impact of the recently completed rationalization process in Quebec and broader industry headwinds. While the rationalization is now concluded, its effects are expected to persist through Q4. Nonetheless, this positions the Company for medium- to long-term benefit as Quebec's cannabis market stabilizes and new categories such as vapes begin to roll out. Notably, Mercanto maintained an adequate working capital position and zero long-term debt. "We are operating in one of the toughest markets, and while results reflect a contraction, we believe our business is resilient and structurally sound," said Eric Ronsse, CEO of Mercanto. "Q3 was a transition quarter as we took most of the impact of rationalization in Quebec, focused on margin-improving products, and on the development of other markets, notably with the launch of three flavours of Deckies THC pouches in New Brunswick. Our strategy remains clear: optimize the mix, minimize waste, and maintain a lean, focused operation. We are building a durable business, not chasing inflated growth." Vape Category Entry & Battery Listing Following the second quarter-end, Mercanto announced it had secured one of only two authorized battery listings for Quebec's new vape category, a strategic win that may help offset short-term softness in financial results and contribute to the Company's post-rationalization recovery, set to launch in Fall 2025. The Company's approved device, the M3B+ from global manufacturer CCELL, will be distributed in all 104 cannabis stores across Quebec. The Quebec cannabis authority has projected that vape products will represent 11% of total provincial cannabis sales within the first year of launch, with approximately 50% of that volume being incremental to the market. In FY2024, Quebec cannabis sales totaled $620 million, indicating a projected vape market of $68 million. Mercanto's battery will be one of only two available to power 25 vape cartridge SKUs. "With the upcoming launch of vapes in Quebec, we are uniquely positioned to benefit from a tightly controlled product rollout where shelf space is limited and quality matters," said Ronsse. "We expect our hardware distribution to be financially positive" The Company has participated in the vape cartridge submission process, with results expected to be announced in the coming weeks. Outlook The Company acknowledges that the cannabis sector remains volatile and more unstable than ever; however, Mercanto's business model has proven resilient, and its future prospects appear increasingly strong. Mercanto's lean structure, cash-focused operations, and diversification into growth segments position it well for long-term value creation. The Company anticipates gradual sales growth as the Quebec rationalization process has now concluded, with its effects expected to last through Q4, positioning the Company to benefit from a more streamlined market environment in the medium to long term. Forward-Looking Information Disclaimer: This press release contains forward-looking information within the meaning of applicable Canadian securities legislation. Forward-looking information typically contains statements with words such as "anticipate," "believe," "expect," "plan," "intend," "estimate," "may," "will," "should," "potential," "proposed," or similar expressions. Forward-looking statements in this document include, but are not limited to, statements regarding Mercanto Holdings Inc.'s future business plans, operations, growth potential, market conditions, product launches, and financial outlook. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. SOURCE Mercanto Holdings Inc.
an hour ago
Canada's GDP shrank in April, with hefty decline in manufacturing
Canada's economy shrank by 0.1 per cent on a monthly basis in April, Statistics Canada said on Friday, with the data agency's advance estimate for May showing a similar decline in activity. The manufacturing sector alone dipped 1.9 per cent — the steepest drop since April 2021, per Statistics Canada — driving a decline among goods-producing industries. Transportation equipment manufacturing was hit hard, which the data agency attributed to uncertainty caused by the trade war in the auto industry as car manufacturers pulled back on production in response to U.S. President Donald Trump's tariff on vehicle exports. Wholesale trade also fell in April, particularly in sub-sectors related to autos and motor vehicle parts, as exports and imports of those products dropped Investment activity largely drove the country's economic growth in April, with the finance and insurance sector growing 0.7 per cent — specifically financial investment services, funds and other financial vehicles. The announcement of U.S. tariffs on April 2 heightened trade tensions and prospects of a global economic slowdown, leading to unusually high activity on Canadian equity markets in April, noted Statistics Canada. That led to a trading frenzy on the Toronto Stock Exchange in the four days that followed the announcement, which the data agency said was the main contributor to elevated activity in April. Public sector activity also rose in April, mostly because of the federal election, while the arts, entertainment and recreation sector increased 2.8 per cent that month as several Canadian NHL teams qualified for the playoffs. Jenna Benchetrit (new window) · CBC News
